This Content Is

Parent & Patient Friendly

> Switch to Clinical Content
The info presented here is from a

Clinical Perspective & May Not Be Suitable For All Audiences

> Switch to Parent & Patient Friendly

What Is Autosomal Recessive Congenital Ichthyosis (ARCI) -  Lamellar Ichthyosis Type?

Autosomal recessive congenital ichthyosis (ARCI) is a recently adopted term referring to a heterogeneous group of disorders that share an autosomal recessive pattern of inheritance, collodion membrane presentation at birth and overlap in causative gene mutations.1  After shedding of the collodion membrane, skin of individuals with ARCI can show a variety of appearances. These different phenotypes have been termed lamellar ichthyosis (LI), congenital ichthyosiform erythroderma (CIE), and harlequin ichthyosis (HI). While significant overlap can occur between phenotypes and individual patients may manifest different phenotypes across their lifetime, these descriptors remain useful in classifying individuals with ARCI and often in predicting the underlying gene mutation.

What are the Signs & Symptoms?

ARCI is a rare disorder, estimated to occur in approximately 1 in 200,000 births.2  At birth, most individuals have a “collodion” presentation, so called because a clear membrane (the collodion) covers their bodies. Sometimes described as having a shellacked appearance, these newborns have skin that is taut, dark and split. Often the eyelids (ectropion) and lips (eclabium) can be forced open by the tightness of the skin, and there may be contractures around the fingers. The collodion membrane is gradually shed over the first few days to weeks of life, after which the skin can take a number of appearances. Such cases usually go on to develop either the LI or CIE phenotypes, with HI being comparatively rare. 

In individuals with the lamellar ichthyosis phenotype, shedding of the collodion membrane reveals dark, plate-like adherent scales with intervening cracks that cover most of the body surface. This build-up of scale is due to the fact that skin cells do not separate normally at the surface of the stratum corneum (the outermost layer of the skin) and are not shed as quickly as they should be. Even after shedding of the collodion membrane, people with lamellar ichthyosis often have trouble closing their eyes completely because of the tightness of the skin around the eyes and eyelids. In some cases, the skin around the eyes pulls so tightly it causes the eyelids to turn outward exposing the inner red lid and causing continuous irritation. This condition is called ectropion. If left untreated, damage to the cornea can develop leading to impaired vision. Treatment with topical retinoids can improve ectropion significantly, and surgical correction is now considered a treatment of last resort. People with lamellar ichthyosis may also have thickened nails and thickened skin on the palms and soles of their feet. Thick scale on the scalp may result in hair loss.  Reddened skin underlying scale (erythroderma) is variable and reflects overlap with the ARCI-CIE phenotype. People with lamellar ichthyosis are at risk for superficial infections of their skin by fungus or bacteria as well as heat intolerance due to decreased sweating.

How is it Diagnosed?

The most common mutation in lamellar ichthyosis occurs in transglutaminase 1 (TGM1), an important enzyme for allowing skin to mature and eventually shed. Other causative mutations have been reported in ATP-binding cassette sub-family A member 12 (ABCA12), cytochrome P450 4F22 (CYP4F22), and ichthyin (NIPAL4).3  In other cases the gene mutation is not known. Mutations in lamellar ichthyosis usually (but not always) are transmitted through autosomal recessive inheritance. Individuals must inherit two recessive genes for lamellar ichthyosis to show the disease, one from each parent. Each parent (“carrier”) shows no evidence of lamellar ichthyosis. (For more information on the genetics of lamellar ichthyosis, request FIRST’s publication, Ichthyosis: The Genetics of its Inheritance).

Results of genetic tests, even when they identify a specific mutation, can rarely tell you how mild or how severe a condition will be in any particular individual. There may be a general presentation in a family or consistent findings for a particular diagnosis, but it's important to know that every individual is different. The result of a genetic test may be "negative," meaning no mutation was identified. This may help the doctor exclude certain diagnoses, although sometimes it can be unsatisfying to the patient. "Inconclusive" results occur occasionally, and this reflects the limitation in our knowledge and techniques for doing the test. But we can be optimistic about understanding more in the future, as science moves quickly and new discoveries are being made all the time. You can receive genetic testing through the Yale University’s Disorders of Keratinization study with Dr. Keith Choate or for more information about genetic tests performed you can visit GeneDx, www.genedx.com

What is the Treatment?

Lamellar ichthyosis is treated topically with skin barrier repair formulas containing ceramides or cholesterol, moisturizers with petrolatum or lanolin, and mild keratolytics (products containing alpha-hydroxy acids or urea). (For more information on which products contain these ingredients, refer to FIRST’s skin care products list.) For people with ectropion, in addition to treatment with topical retinoids, artificial tears or prescription ophthalmic ointments to lubricate the cornea are helpful in preventing eye damage. Severe lamellar ichthyosis can be treated systemically with oral synthetic retinoids (acitretin or isotretinoin). Retinoids are only used in severe cases of ichthyosis due to potential for effects on bones, tendons, and ligaments, and other complications.4,5

Download a PDF version of this information

Click here learn more about clinical trial opportunities for individuals with ARCI-lamellar ichthyosis

Read the November 2013 report on the Galderma Study, Lamellar ichthyosis A qualitative survey in the US and Europe

References:
1.      Oji V, Tadini G, Akiyama M et al. Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sore`ze 2009. Journal of the American Academy of Dermatology. 2010; 63(4): 607-641.
2.      Bale SJ, Richard G. Autosomal Recessive Congenital Ichthyosis. 2001 Jan 10 [Updated 2009 Nov 19]. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-.
3.      Fischer J. Autosomal Recessive Congenital Ichthyosis. J. Invest. Derm. 2009; 129:1319-1321.
4.      Milstone L., McGuire J., Ablow R. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol. 1982; 7:663-666.
5.      Pittsley R.A., Yoder F.W. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med. 1983; 308:1012-1014.

Click to View Clinical Images

Why are the images hidden by default? Can I change this? ?

Clinical ImagesX

Other Names: autosomal recessive congenital ichthyosis (ARCI); lamellar ichthyosis (LI)
OMIM: 242300
Inheritance: autosomal recessive in most cases
Incidence: 1:200,000
Key Findings:
  • skin: generalized flat, polygonal, dark, often large (>1cm) scales; palms and soles usually thickened; variable redness under scales; ectropion usually present; may have clinical overlap with ARCI-CIE type due to shared gene mutations
  • hair: no shaft abnormalities; alopecia has been reported in some cases
  • nails: usually normal; may become dystrophic
Associated Findings:
  • usually none
Age at First Appearance: birth, usually as
Longterm Course: lifelong; skin appearance may evolve early in life but generally stable thereafter; increased susceptibility to bacterial and fungal infections of skin; heat intolerance may be a problem for some
Diagnostic Tests: genetic testing of blood
Abnormal Gene: transglutaminase 1 (TGM1) in many cases; mutations also reported in ATP-binding cassette sub-family A member 12 (ABCA12), cytochrome P450 4F22 (CYP4F22), and ichthyin (NIPAL4).

Additional Resources:

Click here learn more about clinical trial opportunities for individuals with ARCI-lamellar ichthyosis


This information is provided as a service to patients and parents of patients who have ichthyosis. It is not intended to supplement appropriate medical care, but instead to complement that care with guidance in practical issues facing patients and parents. Neither FIRST, its Board of Directors, Medical & Scientific Advisory Board, Board of Medical Editors nor Foundation staff and officials endorse any treatments or products reported here. All issues pertaining to the care of patients with ichthyosis should be discussed with a dermatologist experienced in the treatment of their skin disorder.

Share This Page:

Search